Posts by cowic

The Mitigate Project Agents: A novel PET-CT tracer specifically developed to target cell surface receptors of GIST cells Phase I/IIa Status  Open, recruiting Sponsor Medical University Innsbruck, European Union Further information: www.mitigate-project.eu WHO is the trial for?   Patients with progressive disease who have at least been treated with imatinib are eligible The study addresses…

  Agents: DCC-2618 (Ripretinib) vs. Sunitinib Phase III Status  Closed for recruitment, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03673501   WHO is the trial for? Patients with confirmed advanced or metastatic GIST Patients must have progressed on imatinib or are intolerant to imatinib; patients who had further lines of treatment after imatinib cannot…

Surgery With or Without Radiation Therapy in Treating Patients With Previously Untreated Nonmetastatic Retroperitoneal Soft Tissue Sarcoma (STRASS) Agents: Radiation therapy followed by surgery vs. surgery alone Phase III Status  Open, recruiting Sponsor European Organisation for Research and Treatment of Cancer – EORTC Further information    Link zu Details (to be inserted) WHO is the trial…

Randomized trial of Crenolanib in patients with D842V mutated GIST Trial name CrenoGIST Agents: Crenolanib vs. placebo Phase III Status  Closed, active Sponsor Arog Pharmaceuticals, Inc.   Further information: https://clinicaltrials.gov/ct2/show/NCT02847429?term=crenolanib+Gist&rank=2   WHO is the trial for? Patients with confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene Overall health status of the…

  Agents: DCC-2618 vs. placebo Phase III Status  Closed, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03353753   WHO is the trial for? Patients with confirmed advanced or metastatic GIST with all types of mutation in KIT or PDGFRa (excluded are patients without KIT or PDGFRa mutations) Patients must have progressed on imatinib, sunitinib,…

Selinexor in Advanced Liposarcoma (SEAL) Agents: Selinexor Phase II/III Status  Closed, active Sponsor Karyopharm Therapeutics Inc   Further information: https://clinicaltrials.gov/ct2/show/NCT02606461    This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma (DDLS) WHO is the trial for? Patients of 12 years or older with confirmed DDLS Disease…

Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS) (SUNRISELMS) Agents: Unesbulin in combination with dacabazine Phase II/III Status  Recruiting Sponsor PTC Therapeutics Further information: https://clinicaltrials.gov/ct2/show/NCT05269355 This study compares the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in patients with unresectable or metastatic, relapsed or refractory leiomyosarcoma (LMS) who have received at…

Agents: Radiotherapy Phase II Status  Closed, active Sponsor The Netherlands Cancer Institute   Further information: https://clinicaltrials.gov/ct2/show/NCT02106312   WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…

This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status  Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and pazopanib vs. pazopanib alone in patients with advanced angiosarcoma (TAPPAS).Further information: https://www.clinicaltrials.gov/ct2/show/study/NCT02979899?term=tracon&cond=Angiosarcoma&rank=1&show_locs=Y#locn  …